Dr. Hari Kumar is a pharmaceutical executive with over 25 years of experience in the industry, ranging from research and lifecycle management to business development, mergers & acquisitions and partnering. Having trained as an immunologist at University College London where he completed his PhD, Dr. Kumar completed a postdoctoral fellowship at Tufts New England Medical Center in Boston and another fellowship at the Marie Curie Cancer Research Centre in UK.
Dr. Kumar started his pharmaceutical career at Roche. Between 1996 to 1999, Dr. Kumar was the European Marketing Director for Eisai Ltd before returning to Roche in 1999 as Global Head of Transplant Immunosuppressives. He moved to Amira Pharmaceuticals Inc in 2007 as Chief Business Officer and after Amira’s acquisition in 2011, was Chief Executive Officer of Panmira Pharmaceuticals LLC. In 2013, Dr. Kumar became Chief Executive Officer of Adheron Therapeutics, Inc which he led until the successful acquisition of the company in 2015.
Dr. Kumar has overseen the launch of the immunosuppressive, CellCept®, the Alzheimer’s drug, Aricept® and gastric ulcer drug, Aciphex®. He has been actively involved in helping biotech startups with their strategies either as an independent board member or as consultant to the CEO.